ARTBIO announces the appointment of Dr. Nick Pullen announced as Chief Scientific Officer
17.10.2023 14:58
ARTBIO, a clinical-stage radiopharmaceutical company developing a new category of alpha-radioligand targeted therapies (ART), today announced the appointment of Dr. Nick Pullen announced as Chief Scientific Officer.
Dr. Pullen has more than 20 years of biopharmaceutical leadership experience and has led drug discovery programs spanning multiple genetic categories, modalities and indications, including oncology, neuroscience and immunology. In this role, Dr. Pullen will be responsible for overseeing all scientific research efforts to further advance ARTBIO's scientific approach to radiopharmaceuticals and advance the company's differentiated programs.
“We are pleased to welcome Nick to our team at this pivotal time for ARTBIO. “Nick brings a wealth of highly relevant and valuable expertise in the discovery and development of innovative therapies in various disease areas,” stated Dr. Emanuele Ostuni, Managing Director of ARTBIO. “I am confident that his extensive experience and commitment to delivering medicines to patients will be an important contributor to building our R&D strategy as we develop our range of alpha radioligand therapies based on the ideal Pb212 isotope develop.
Before joining ARTBIO, Dr. Pullen senior vice president and head of research at Jnana Therapeutics. There he was involved in Series B and C financings, which together raised more than $150 million. He also led a multi-target partnership with Roche, established a research suite and brought the allosteric SLC6A19 inhibitor into development for the treatment of PKU. Before joining Jnana, Dr. Pullen was Vice President of Integrative Sciences at Celgene/BMS and worked at Pfizer in several scientific leadership positions. In both companies, Dr. Pullen is responsible for the scientific and strategic leadership of numerous drug development programs. Dr. Pullen received his PhD in GPCR pharmacology from the University of Southampton in the United Kingdom and completed a postdoctoral fellowship at the Friedrich Miescher Institute in Basel, Switzerland. He has more than 50 peer-reviewed publications, patents, and book chapters.
“Radiopharmaceuticals may be one of the most promising new approaches for targeted cancer therapy. I am excited to join ARTBIO at this time in the company's growth and to combine the unique AlphaDirect™ technology and powerful action of Pb212 with sophisticated biology and chemistry to develop a broad portfolio of targeted cancer therapies that have the potential to... “To redefine cancer treatment,” said Dr. Pullen.